

INTERNATIONAL CONGRESS
MULTIPLE MYELOMA
and related malignancies

7th EDITION



Presidents

Prof. Angelo Vacca, Prof. Roberto Ria

BARI (ITALY)
November 7-9, 2024

The Nicolaus Hotel, Bari (Italy)



UNIVERSITÀ
DEGLI STUDI DI BARI
ALDO MORO



SIE - Società Italiana di Ematologia



SIMI
SOCIETÀ ITALIANA
DI MEDICINA INTERNA
Patrocinio



REGIONE PUGLIA

Patrocinio del Presidente della Giunta
Regionale, concesso
con Decreto n° 323 del 16/07/2024

SCIENTIFIC SECRETARIAT

Sebastiano Cicco
Vanessa Desantis
Ilaria Saltarella
Antonio Solimando

In the last 20 years remarkable advancements in the understanding of the pathophysiology of Multiple Myeloma and related malignancies have paved the way to the identification and the subsequent adoption of new effective and safe therapies. Following the 6th edition which was held on November 5-7th, 2022, the time has come for a thorough biological and clinical update. Like in the previous editions, we aim to provide hematologists, oncologists, internists, radiologists, and other medical specialists as well as young researchers, residents, doctoral and undergraduate students with an invaluable opportunity to deepen and update their knowledge on the already acquired and emerging developments in the biology and treatment of Multiple Myeloma and related malignancies.

A number of internationally renowned speakers have been invited to deliver state of the art lectures on cutting edge topics. These will include genetic and epigenetic features of myeloma biology, molecular and biological mechanisms of disease progression, new prognostic markers and novel approaches to assess the response to therapy, new single or combined therapeutic molecules specifically targeting tumor cells and/or their microenvironment. Autologous and allogeneic stem cell transplantation, bispecific monoclonal antibodies, and CAR-T cells will also be the object of intensive scrutiny. Finally, supportive therapy, emerging toxicity, and infectious complications will be discussed in their many facets.

We are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by Multiple Myeloma and cognate tumors may now be approached with more rational and more effective achievements.

Angelo Vacca, Roberto Ria

FACULTY

ACCARDI FABRIZIO	PALERMO (IT)	KUMAR SHAJI	ROCHESTER (USA)
AMODIO NICOLA	CATANZARO (IT)	LUND THOMAS	ODENSE (DK)
BAHLIS NIZAR JACQUES	CALGARY (CAN)	MANIER SALOMON	LILLE (FR)
BEKSAC MERAL	ANKARA (TR)	MILANI PAOLO	PAVIA (IT)
BELLONE MATTEO	MILAN (IT)	MINA ROBERTO	TURIN (IT)
BOLLI NICCOLO'	MILAN (IT)	MORELLI EUGENIO	CANDIOLO (IT)
BOTTA CIRINO	PALERMO (IT)	MUSTO PELLEGRINO	BARI (IT)
BRUNO BENEDETTO	TURIN (IT)	NERI PAOLA	CALGARY (CAN)
CERCHIONE CLAUDIO	MELDOLA (IT)	RIA ROBERTO	BARI (IT)
CORSO ALESSANDRO	LEGNANO (IT)	ROCCARO ALDO MARIA	BRESCIA (IT)
CUPEDO TOM	ROTTERDAM (NL)	ROMANO ALESSANDRA	CATANIA (IT)
DA VIA' MATTEO	MILAN (IT)	SCHJESVOLD FREDRIK	OSLO (NO)
D'AGOSTINO MATTIA	TURIN (IT)	SECKINGER ANJA	JETTE (BE)
DAMMACCO FRANCO	BARI (IT)	SOLIMANDO A. GIOVANNI	BARI (IT)
DE LA RUBIA COMOS JAVIER	VALENCIA (ES)	TACCHETTI PAOLA	BOLOGNA (IT)
DE VEIRMAN KIM	BRUSSELS (BE)	TERRAGNA CAROLINA	BOLOGNA (IT)
DERUDAS DANIELE	CAGLIARI (IT)	VACCA ANGELO	BARI (IT)
EINSELE HERMANN	WÜRZBURG (DE)	VAN RIET IVAN	BRUSSELS (BE)
GAY FRANCESCA	TURIN (IT)	VANDERKERKEN KARIN	BRUSSELS (BE)
GIULIANI NICOLA	PARMA (IT)	VARETONI MARZIA	PAVIA (IT)
GULLA' ANNAMARIA	CANDIOLO (IT)	WEINHOLD NIELS	HEIDELBERG (DE)
JACKSON GRAHAM H.	NEWCASTLE (UK)	WILLENBACHER ELLA	INNSBRUCK (AT)
JAKUBOWIAK ANDRZEJ J.	CHICAGO (USA)	WILLENBACHER WOLFGANG	INNSBRUCK (AT)
JOLLES STEPHEN	CARDIFF (UK)		

- 13.30-14.15 Registration of participants
- 14.15-14.30 Welcome speech and orientation
Angelo Vacca, Roberto Ria
- 14.30-15.10 Opening Lecture
Chairperson: Angelo Vacca
- Role of the immune microenvironment in resistance to T-cell based therapies
Paola Neri

15.10-17.15 Workshop 1 _____

Biology: Genomic, Epigenomic and Proteomic of Multiple Myeloma and Precursors
Chairpersons: Niccolò Bolli, Andrzej J. Jakubowiak

- 15.10-15.35 The supportive role of the endothelial niche in myeloma biology
Aldo M. Roccaro
- 15.35-16.00 Mitochondrial dysfunctions in Multiple Myeloma
Nicola Amodio
- 16.00-16.25 Genomic complexity during smoldering Multiple Myeloma progression
Matteo Da Vià
- 16.25-16.50 Transcriptome of Multiple Myeloma
Anja Seckinger
- 16.50-17.15 Circulating tumor cells in Multiple Myeloma
Andrzej J. Jakubowiak
- 17.15-17.30 *Coffee break*

17.30-19.35 Workshop 2 _____

Biology: Bone Disease and Immunodeficiency in Myeloma
Chairperson: Tom Cupedo, Karin Vanderkerken

- 17.30-17.55 New acquisition on myeloma bone disease pathogenesis
Nicola Giuliani
- 17.55-18.20 Dendritic cells in Multiple Myeloma
Kim De Veirman
- 18.20-18.45 The nutrition-microbiota-immunity axis in Multiple Myeloma
Matteo Bellone
- 18.45-19.10 The tumor-supportive microenvironment in Multiple Myeloma
Tom Cupedo
- 19.10-19.35 Mesenchymal stem cells in Multiple Myeloma
Ivan Van Riet

08.30-11.00 Workshop 3

Prognostic Stratification and Big Data

Chairpersons: Mattia D'Agostino, Ella Willenbacher

08.30 - 08.55 Impact of genomic complexity on prognosis of Multiple Myeloma
Niccolò Bolli

08.55 - 09.20 Unraveling the biological underpinnings of tumor immune escape
Annamaria Gullà

09.20 - 09.45 1q abnormalities for Multiple Myeloma risk stratification
Mattia D'Agostino

09.45 - 10.10 Next generation sequencing or next generation flow for MRD evaluation
Carolina Terragna

10.10 - 10.35 Role of registry to increase knowledge on Multiple Myeloma
Wolfgang Willenbacher

10.35 - 11.00 High risk disease beyond CAR-T and BiTEs: Machine learning guided approaches
Antonio Giovanni Solimando

11.00 - 11.20 *Coffee break*

11.20-13.00 Workshop 4

Clinical Features

Chairpersons: Franco Dammacco, Stephen Jolles

11.20 - 11.45 From targeted to cellular therapy: an unexpected role for RNA?
Eugenio Morelli

11.45 - 12.10 Treatment of secondary immunodeficiency and infections in Multiple Myeloma
Stephen Jolles

12.10 - 12.35 Monoclonal gammopathies of clinical significance
Daniele Derudas

12.35 - 13.00 Secondary primary malignancies in Multiple Myeloma
Graham H. Jackson

13.00 - 14.30 *Lunch*

14.30 - 15.00 Keynote Lecture
Chairperson: Franco Dammacco

CAR-T and beyond in Multiple Myeloma
Nizar Jacques Bahlis

15.00-16.40 Workshop 5

First Line Therapy

Chairpersons: Alessandro Corso, Salomon Manier

15.00 - 15.25

New evidence on induction therapy in transplantable patients

Alessandro Corso

15.25 - 15.50

Upfront therapy in transplantable patients: can we develop a personalized strategy?

Francesca Gay

15.50 - 16.15

How I treat high-risk myeloma

Paola Tacchetti

16.15 - 16.40

Special problems in the management of elderly patients with Multiple Myeloma

Salomon Manier

16.40 - 17.00

*Coffee break***17.00-19.05 Workshop 6**

Relapsed/Refractory Myeloma

Chairpersons: Roberto Ria, Fredrik Schjesvold

17.00 - 17.25

New strategies for first relapsed patients

Ciro Botta

17.25 - 17.50

Over the second relapse

Alessandra Romano

17.50 - 18.15

Unmet medical need for lenalidomide refractory myeloma patients

Javier de la Rubia Comos

18.15 - 18.40

New combination of anti-CD38 monoclonal antibodies

Fredrik Schjesvold

18.40 - 19.05

MRD-guided therapeutic strategies

Roberto Mina

08.30-11.00 Workshop 7

Newest Drugs and Strategies

Chairpersons: Shaji Kumar, Thomas Lund

08.30 - 08.55 Development of new clinical trial in Multiple Myeloma
Shaji Kumar

08.55 - 09.20 Pathway-directed therapy in Multiple Myeloma
Niels Weinhold

09.20 - 09.45 Selinexor therapy for Multiple Myeloma
Claudio Cerchione

09.45 - 10.10 Targeting B cell maturation antigen (BCMA) in Multiple Myeloma
Hermann Einsele

10.10 - 10.35 CelMod a new treatment of relapsed/refractory disease
Fabrizio Accardi

10.35 - 11.00 Emerging antigen target for Multiple Myeloma immunotherapy
Benedetto Bruno

11.00 - 11.30 *Coffee break*

11.30-13.10 Workshop 8

Plasma Cell Dyscrasias

Chairpersons: Pellegrino Musto, Marzia Varettoni

11.30 - 11.55 Molecular classification, diagnosis, and evidence-based treatment of plasma cell leukaemia
Thomas Lund

11.55 - 12.20 Extramedullary myeloma
Meral Beksac

12.20 - 12.45 Current approach to Waldenström macroglobulinemia
Marzia Varettoni

12.45 - 13.10 New strategies for insoluble organ-deposited amyloid depletion
Paolo Milani

13.10 - 13.25 Closing Remarks
Angelo Vacca, Roberto Ria

Congress Closure and CME questionnaire

VENUE

The Nicolaus Hotel
Via Cardinale Agostino Ciasca 27
Bari (Italy)

REGISTRATION

Attendance is free of charge.
Registration can be made through the website www.meeting-planner.it (select the congress in the section "Calendario eventi" - Eventi).

CONTINUING MEDICAL EDUCATION (CME) - event n. 428411

This Congress has been assigned n. **11,9** credits.
This training event is for **200** attendees. Medical specialists in the following areas:
Internal Medicine, Allergology and Clinical Immunology, Hematology, Oncology, Infectious diseases, Radiology, Radiotherapy, Orthopedics and traumatology and Clinical Biochemistry.
Other healthcare professionals: Biologists and Nurses.

CME credits can be claimed and your CME certificate issued only if you:

- have attended the entire training event
- have passed the CME assessment survey (a score of 75% or higher must be attained)

There can be no exceptions to these mandatory steps.

Attendants are also required not to exceed acquiring over 1/3 of their credits for the three-year period (2020-2022) by recruitment invitation.

AIMS OF THE TRAINING PROCESS

Guidelines, Protocols, Procedures (2)

LANGUAGE

The official language is English.

PROVIDER AND ORGANIZING SECRETARIAT

MEETING PLANNER

Provider ECM Nazionale Accreditato n. 2516

Via Divisione Paracadutisti Folgore, 5 - 70125 BARI
TEL. 080.9905360 - FAX 080.9905359 - 080.2140203

E-mail: info@meeting-planner.it - www.meeting-planner.it

SISTEMA DI GESTIONE
QUALITÀ CERTIFICATO



UNI EN ISO 9001:2015

SISTEMA DI GESTIONE
PARITÀ DI GENERE



UNIPDR 125:2022

